key: cord-1008502-air9csu8 authors: Khayat-Khoei, Mahsa; Conway, Sarah; Rubinson, Douglas A.; Jarolim, Petr; Houtchens, Maria K. title: Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab date: 2021-02-27 journal: J Neurol DOI: 10.1007/s00415-021-10463-3 sha: f5d97ab66c9d99c24ffc67745bb4858c5a5f70f1 doc_id: 1008502 cord_uid: air9csu8 nan A 44-year-old Caucasian male presented 4 years ago with symptomatic myelitis and multifocal demyelinating T2 and T1 Gadolinium contrast enhancing (T1Gd +) lesions throughout the brain and spinal cord. He was diagnosed with Relapsing Remitting MS (RRMS), initiated on semi-annual ocrelizumab therapy and had no evidence of disease activity (NEDA) for 3.5 years. He had been repeatedly tested for the presence of SARS-CoV-2 by RT-PCR through the institutional research program (Fig. 1) . He received his first dose of SARS-CoV-2 (Pfizer) vaccine 5 months after ocrelizumab infusion, followed by the second dose 21 days later. There was a moderate post-vaccination systemic reaction with myalgias and fatigue. He received another ocrelizumab infusion 9 days after the second dose of the vaccine (Fig. 1) . The decision to receive treatment on schedule was made considering his excellent therapeutic response to date with on-label use of ocrelizumab. On the day of infusion, he had complete depletion of CD19 + and CD20 + but Immunoglobulin G (IgG) level and Absolute Lymphocyte Count (ANC) were normal ( Fig. 1 ). At the time of infusion he tested negative for antibodies to the SARS-CoV-2 nucleoplasmid antigen (Roche Elecsys Anti-SARS-CoV-2), an assay that interrogates for a humoral immune response to SARS-CoV-2 indicating prior infection [6] . This assay does not reflect an immune response from the mRNA vaccines, directed against virus spike but not nucleocapsid protein. 27 days after the second vaccine dose and 18 days after ocrelizumab infusion, the patient was tested using the Roche Elecsys Anti-SARS-CoV-2 S assay ( Fig. 1 ). This assay is intended for qualitative and semiquantitative detection of antibodies to the SARS-CoV-2 spike (S) protein receptorbinding domain. It is designed to detect adaptive immune response indicating prior infection, and to uniquely detect SARS-Cov-2 anti-S antibodies post mRNA vaccination [7] . Based on the manufacturer's internal studies in healthy subjects and patients infected with SARS-CoV-2 (positive RT-PCR), the assay is highly specific with a negative predictive value (NPV) of 99.98, while its sensitivity increases from 90.6% 0-7 days after confirmed infection to 96.6% > = 15 days after positive RT-PCR [8] . The result of this spike antibody assay was negative in our patient indicating no measurable post-vaccination immunity (negative results < 0.40 U/mL). To our knowledge, this is the first report of SARS-COV-2 vaccine response in a patient with multiple sclerosis on intravenous anti-CD20 therapy. There are cases of negative SARS-CoV-2 IgG assays in MS patients with PCR-confirmed COVID-19 infection on ocrelizumab [2] [3] [4] . A recent publication of persistent anti-SARS-CoV-2 IgG antibodies following COVID19 infection in patient on ofatumumab, suggests a detectable humoral response to SARS-CoV-2 [9] . Another investigation indicates that binding titers to spike receptor-binding domain (RBD) protein as assessed on enzyme-linked immunosorbent assay (ELISA) are significantly increased on day 15 post initial 100-μg dose of mRNA-1273 vaccination [10] . Further, unpublished internal validation studies in 24 healthy volunteers for Anti-SARS-CoV-2 S assay at our institution (Dr. Petr Jarolim) suggest positive anti-spike serology after the first dose of mRNA vaccine in all subjects, with some showing titers greater than 250 U/mL (analytical measurement range). The VELOCE trial in RRMS patients showed attenuated but present humoral responses following pneumococcal, influenza and tetanus toxoid vaccinations upon initiation of ocrelizumab [5] . Blunted immunity to hepatitis B vaccine has been observed in patients on rituximab [11, 12] . Ocrelizumab does not affect plasma cells directly and naïve B-cells generally recover significantly faster than memory B-cells [12] . Our patient did not seroconvert when tested 27 days after the second dose of the Pfizer mRNA vaccine. It is likely that antibody response would have been generated after the 1st and the 2nd vaccine doses, 5 months after the prior infusion, despite re-treatment with ocrelizumab on day 9 post-vaccination (Fig. 1 ). However, it is possible that early re-treatment with ocrelizumab may have further dampened post-vaccination immunity. Our case documents undetectable humoral response after mRNA SARS-CoV-2 vaccination in a B-cell depleted patient and this is potentially concerning. However, the clinical relevance of this result is unclear as it may not indicate a complete absence of an immunity to the wild type SARS-CoV-2 infection [2, 10] In this setting, the formation of antigen-specific cytotoxic anti-viral T cells may help provide some protection. It is not known if the absence of Anti-SARS-CoV-2 S antibodies reflects suboptimal vaccine response and whether delaying anti-CD20 treatments to allow B cell reconstitution before administering COVID-19 mRNA vaccine may be warranted in some patients [2, 9] Larger studies investigating COVID-19 mRNA vaccine response in patients on anti-CD20 treatments are essential to define the optimal "vaccination window." Author contributions statements All authors contributed to the study conception and design. The first draft of the manuscript was written by Mahsa Khayat-Khoei and all authors edited subsequent versions of the manuscript. All authors read and approved the final draft. Ethics approval All studies performed at the Brigham and Women's Hospital are approved by the appropriate ethics committee and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Vaccines for COVID-19 Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study Detection of SARS-CoV-2 IgG targeting nucleocapsid or spike protein by four high-throughput immunoassays authorized for emergency use The COVID-19 serology studies workshop: recommendations and challenges Diagnostics Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases